Literature DB >> 15105103

Identification and characterization of inhibitors of bacterial enoyl-acyl carrier protein reductase.

Losee L Ling1, Jun Xian, Syed Ali, Bolin Geng, Jun Fan, Debra M Mills, Anthony C Arvanites, Hernan Orgueira, Mark A Ashwell, Gilles Carmel, Yibin Xiang, Donald T Moir.   

Abstract

Bacterial enoyl-acyl carrier protein reductase (ENR) catalyzes an essential step in fatty acid biosynthesis. ENR is an attractive target for narrow-spectrum antibacterial drug discovery because of its essential role in metabolism and its sequence conservation across many bacterial species. In addition, the bacterial ENR sequence and structural organization are distinctly different from those of mammalian fatty acid biosynthesis enzymes. High-throughput screening to identify inhibitors of Escherichia coli ENR yielded four structurally distinct classes of hits. Several members of one of these, the 2-(alkylthio)-4,6-diphenylpyridine-3-carbonitriles ("thiopyridines"), inhibited both purified ENR (50% inhibitory concentration [IC(50)] = 3 to 25 micro M) and the growth of Staphylococcus aureus and Bacillus subtilis (MIC = 1 to 64 micro g/ml). The effect on cell growth is due in part to inhibition of fatty acid biosynthesis as judged by inhibition of incorporation of [(14)C]acetate into fatty acids and by the increased sensitivity of cells that underexpress an ENR-encoding gene (four- to eightfold MIC shift). Synthesis of a variety of compounds in this chemical series revealed a correlation between IC(50) and MIC, and the results provided initial structure-activity relationships. Preliminary structure-activity relationships, potency on purified ENR, and activity on bacterial cells indicate that members of the thiopyridine chemical series are effective fatty acid biosynthesis inhibitors suitable for further antibacterial development.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15105103      PMCID: PMC400533          DOI: 10.1128/AAC.48.5.1541-1547.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

2.  Molecular basis of triclosan activity.

Authors:  C W Levy; A Roujeinikova; S Sedelnikova; P J Baker; A R Stuitje; A R Slabas; D W Rice; J B Rafferty
Journal:  Nature       Date:  1999-04-01       Impact factor: 49.962

3.  A triclosan-resistant bacterial enzyme.

Authors:  R J Heath; C O Rock
Journal:  Nature       Date:  2000-07-13       Impact factor: 49.962

4.  Evidence that TolC is required for functioning of the Mar/AcrAB efflux pump of Escherichia coli.

Authors:  J A Fralick
Journal:  J Bacteriol       Date:  1996-10       Impact factor: 3.490

5.  Multiple mechanisms of action for inhibitors of histidine protein kinases from bacterial two-component systems.

Authors:  J J Hilliard; R M Goldschmidt; L Licata; E Z Baum; K Bush
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

6.  Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents.

Authors:  M A Seefeld; W H Miller; K A Newlander; W J Burgess; D J Payne; S F Rittenhouse; T D Moore; W E DeWolf; P M Keller; X Qiu; C A Janson; K Vaidya; A P Fosberry; M G Smyth; D D Jaworski; C Slater-Radosti; W F Huffman
Journal:  Bioorg Med Chem Lett       Date:  2001-09-03       Impact factor: 2.823

7.  1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI).

Authors:  D A Heerding; G Chan; W E DeWolf; A P Fosberry; C A Janson; D D Jaworski; E McManus; W H Miller; T D Moore; D J Payne; X Qiu; S F Rittenhouse; C Slater-Radosti; W Smith; D T Takata; K S Vaidya; C C Yuan; W F Huffman
Journal:  Bioorg Med Chem Lett       Date:  2001-08-20       Impact factor: 2.823

Review 8.  Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics.

Authors:  R J Heath; S W White; C O Rock
Journal:  Appl Microbiol Biotechnol       Date:  2002-03-07       Impact factor: 4.813

9.  Discovery of a novel and potent class of FabI-directed antibacterial agents.

Authors:  David J Payne; William H Miller; Valerie Berry; John Brosky; Walter J Burgess; Emile Chen; Walter E DeWolf; Andrew P Fosberry; Rebecca Greenwood; Martha S Head; Dirk A Heerding; Cheryl A Janson; Deborah D Jaworski; Paul M Keller; Peter J Manley; Terrance D Moore; Kenneth A Newlander; Stewart Pearson; Brian J Polizzi; Xiayang Qiu; Stephen F Rittenhouse; Courtney Slater-Radosti; Kevin L Salyers; Mark A Seefeld; Martin G Smyth; Dennis T Takata; Irene N Uzinskas; Kalindi Vaidya; Nicola G Wallis; Scott B Winram; Catherine C K Yuan; William F Huffman
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

10.  Use of the Escherichia coli lac repressor and operator to control gene expression in Bacillus subtilis.

Authors:  D G Yansura; D J Henner
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

View more
  17 in total

1.  Structural and enzymatic analyses reveal the binding mode of a novel series of Francisella tularensis enoyl reductase (FabI) inhibitors.

Authors:  Shahila Mehboob; Kirk E Hevener; Kent Truong; Teuta Boci; Bernard D Santarsiero; Michael E Johnson
Journal:  J Med Chem       Date:  2012-06-08       Impact factor: 7.446

2.  Crystallization and preliminary X-ray analysis of enoyl-acyl carrier protein reductase (FabK) from Streptococcus pneumoniae.

Authors:  Jun Saito; Mototsugu Yamada; Takashi Watanabe; Hideo Kitagawa; Yasuo Takeuchi
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2006-05-31

3.  Crystallization and preliminary X-ray crystallographic analysis of enoyl-ACP reductase III (FabL) from Bacillus subtilis.

Authors:  Kook-Han Kim; Joon Kyu Park; Byung Hak Ha; Jin Ho Moon; Eunice EunKyeong Kim
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-02-28

4.  AG205, a novel agent directed against FabK of Streptococcus pneumoniae.

Authors:  Sho Takahata; Maiko Iida; Yumi Osaki; Jun Saito; Hideo Kitagawa; Tomohiro Ozawa; Takuji Yoshida; Shigeru Hoshiko
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

5.  New 2-thiopyridines as potential candidates for killing both actively growing and dormant Mycobacterium tuberculosis cells.

Authors:  Elena Salina; Olga Ryabova; Arseny Kaprelyants; Vadim Makarov
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

Review 6.  Challenges of antibacterial discovery.

Authors:  Lynn L Silver
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

7.  Purification, crystallization and preliminary X-ray diffraction analysis of enoyl-acyl carrier protein reductase (FabK) from Streptococcus mutans strain UA159.

Authors:  Tae-O Kim; Dong-Won Im; Ha Yun Jung; Seong Jung Kwon; Yong-Seok Heo
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-02-22

8.  Rational questing for potential novel inhibitors of FabK from Streptococcus pneumoniae by combining FMO calculation, CoMFA 3D-QSAR modeling and virtual screening.

Authors:  Qingye Zhang; Chan Yu; Jun Min; Yan Wang; Jin He; Ziniu Yu
Journal:  J Mol Model       Date:  2010-09-23       Impact factor: 1.810

9.  The MUT056399 inhibitor of FabI is a new antistaphylococcal compound.

Authors:  S Escaich; L Prouvensier; M Saccomani; L Durant; M Oxoby; V Gerusz; F Moreau; V Vongsouthi; Kirsty Maher; Ian Morrissey; C Soulama-Mouze
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

10.  Mechanism and inhibition of saFabI, the enoyl reductase from Staphylococcus aureus.

Authors:  Hua Xu; Todd J Sullivan; Jun-ichiro Sekiguchi; Teruo Kirikae; Iwao Ojima; Christopher F Stratton; Weimin Mao; Fernando L Rock; M R K Alley; Francis Johnson; Stephen G Walker; Peter J Tonge
Journal:  Biochemistry       Date:  2008-03-13       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.